Evidence map›Paper›PMID 25934461›Full record

ReviewCold Spring Harbor perspectives in medicine2015

Hepatitis B virus epidemiology.

Jennifer H MacLachlan, Benjamin C Cowie

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04029454 (Neovac 2 Burkina Faso), which is not on this map. Cited by 156 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04029454 nacompletednot on this mapstarted 2020, after this paper: background citation

Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule: a Mixed Methods Study Including a Cluster-randomized Trial, an Anthropological Study and an Economic Evaluation

TypeinterventionalSponsorInstitut PasteurRan2020 to 2023Enrolled10,000ConditionsHepatitis BArmsbirth dose vaccination against hepatitis B strategy
3 · Its place in the literature

Who cites it

156 citing papers in PubMed, 5 syntheses or guidelines pooled it, 336 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article

96 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jennifer H MacLachlanEpidemiology Unit, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Melbourne, Victoria 3000, Australia Department of Medicine, University of Melbourne, Melbourne, Victoria 3050, Australia.
Benjamin C CowieEpidemiology Unit, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Melbourne, Victoria 3000, Australia Department of Medicine, University of Melbourne, Melbourne, Victoria 3050, Australia Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia.
The Royal Melbourne Hospital · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epidemiology of hepatitis B virus (HBV) infection is geographically diverse, with population prevalence, age and mode of acquisition, and likelihood of progression to chronic infection mutually interdependent. The burden of chronic HBV infection is increasingly being recognized, with cirrhosis and liver cancer attributable to HBV continuing to increase. The outcomes of chronic HBV infection are affected by a range of factors, including viral genotype, the presence of coinfections with other blood-borne viruses, and the impact of other causes of liver disease. The increased recognition of HBV infection as a leading cause of death globally has resulted in the development of new structures and policies at the international level; immediate attention to implementing these strategies is now required.

Indexed as

Carcinoma, HepatocellularDNA, ViralHepatitis B, ChronicHepatitis B virusHumansLiver CirrhosisLiver NeoplasmsRisk FactorsDNA, Viral

Identifiers

PMID25934461
PMCPMC4448582
OpenAlexW2109056360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.